| abstract |
Disclosed are substituted pyrazine compounds represented by general formula (I), wherein M1 and M2 are substituted pyrazines and the other substituents are defined within the specification. Examples of the compounds of formula (I) include N,N'-(1,1'-(1,4-phenylenebis(methylene))bis(azanediyl) bis(oxomethylene)bis(piperidine-4,1- diyl))bis(azanediyl) bis(iminomethylene)bis(3,5-diamino-6-chloropyrazine-2-carboxamide); N,N'-(1,1'-(1,4-phenylenebis(azanediyl))bis(oxomethylene)bis(piperidine-4,1-diyl))bis(azanediyl)bis(iminomethylene)bis(3,5-diamino-6-chloropyrazine-2-carboxamide); and N,N'-(1,1'-(cyclohexane-1,3-diylbis(methylene))bis(azanediyl)bis(oxomethylene)bis(piperidine-4,1-diyl))bis(azanediyl)bis (iminomethylene)bis(3,5-diamino-6-chloropyrazine-2-carboxamide); Also disclosed is the use of the compounds of formula (I) for treating cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infection, lung carcinoma, xerostomia, keratoconjunctivitis or a disease treatable by the blockade of an epithelial sodium channel. |